Apellis Pharmaceuticals, Inc.
Clinical trials sponsored by Apellis Pharmaceuticals, Inc., explained in plain language.
-
New drug pegcetacoplan tested in teens with rare blood disorder
Disease control Recruiting nowThis study tests a drug called pegcetacoplan in 12 to 17-year-olds with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The drug aims to control the disease by blocking part of the immune system. The trial will check safety, how the…
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to halt blindness from 'Dry' macular degeneration
Disease control Recruiting nowThis Phase 2 trial tests whether adding APL-3007 to the existing drug Syfovre (pegcetacoplan) can better slow geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 240 adults aged 60 and older with the condition will receive e…
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC